Organigram Global Inc. (OGI) Balance Sheet

Retained earnings remained deeply negative at -$484.1M in 2026Q3, which indicates the company has not generated cumulative profits and the equity base depends on paid-in capital. The sharp step-up in goodwill and PPE alongside the 2026Q3 acquisition outflow suggests the asset growth is acquisition-driven, and investors should monitor whether the acquired assets produce returns sufficient to justify the added balance sheet weight.

A current ratio above 2.5 typically signals comfortable short-term coverage, yet with cash of only $10.9M against persistent negative operating cash flow, the headline ratio appears to overstate immediate flexibility. The contraction from $106.7M of cash in 2024Q4 to the current level warrants further investigation into how quickly current assets convert to cash during a cash-burning period.

Debt rose from negligible levels in 2024 to $21.0M, a move that may reflect acquisition financing or working capital needs rather than a strategic capital structure decision. Because the reported debt load is small relative to the equity base, refinancing risk appears limited, though the lack of profitable operations means debt service would ultimately depend on the cash generation that has so far been absent.

A near-quadrupling of goodwill in a single quarter alongside a $125.0M net acquisition outflow suggests a significant transaction, and the balance sheet may carry impairment risk if the acquired operations underperform given OGI's history of losses. PPE net remaining stable near $121M indicates the core manufacturing base has been steady, so the asset expansion appears concentrated in intangibles rather than productive capacity.